<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773770</url>
  </required_header>
  <id_info>
    <org_study_id>UX007-EAP</org_study_id>
    <secondary_id>UX007G-EAP102</secondary_id>
    <nct_id>NCT03773770</nct_id>
  </id_info>
  <brief_title>Expanded Access to Triheptanoin</brief_title>
  <official_title>An Open-label Intermediate-size Treatment Protocol for the Urgent Treatment of Seriously Ill Patients With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) With Triheptanoin (UX007)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <brief_summary>
    <textblock>
      Expanded access may be provided for qualified patients who have limited treatment options and&#xD;
      are not eligible for a clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS): Available through&#xD;
      Intermediate-Size Population Expanded Access.&#xD;
&#xD;
      The intermediate-size expanded access treatment protocol is intended to provide rapid access&#xD;
      to triheptanoin for the treatment of seriously ill patients with Glut1 DS.&#xD;
&#xD;
      Patients will be treated under this protocol for the duration of one year, with consideration&#xD;
      on a yearly basis for extension of treatment based on the risk-benefit ratio assessed in the&#xD;
      Treating Physician's quarterly progress reports. Patients may continue to receive&#xD;
      triheptanoin under this intermediate-size treatment protocol until commercial availability of&#xD;
      triheptanoin, should the drug receive regulatory approval for the specific disease&#xD;
      indication.&#xD;
&#xD;
      Long Chain Fatty Acid Oxidation Disorders (LC-FAOD) and Non-FAOD conditions: Available&#xD;
      outside of the United States through individual named patient compassionate access requests.&#xD;
&#xD;
      Expanded access may provide access for treatment prior to approval by the local regulatory&#xD;
      agency.&#xD;
&#xD;
      For full details, please visit the link provided.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triheptanoin</intervention_name>
    <description>Liquid for oral (PO) or enteral tube administration</description>
    <other_name>UX007</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria per Intermediate-Size Population Protocol for Glut1 DS&#xD;
&#xD;
          -  Confirmed diagnosis of Glut1 DS by documented SLC2A1 mutation or documented&#xD;
             improvement on other forms of tripheptanoin administered based on a clinical&#xD;
             presentation consistent with Glut1 DS diagnosis, including cerebrospinal fluid glucose&#xD;
             levels.&#xD;
&#xD;
          -  Patients of any age who are seriously ill and, in the Treating Physician's opinion,&#xD;
             experiencing clinical manifestations of Glut1 DS despite other management.&#xD;
&#xD;
          -  Willing and able to comply with all aspects of the treatment, including visits and&#xD;
             tests specified by the Treating Physician, documentation of symptoms and diet, and&#xD;
             administration of triheptanoin. If a minor, have a caregiver(s) willing and able to&#xD;
             assist in all applicable treatment requirements.&#xD;
&#xD;
          -  Provide written informed consent (patients aged â‰¥ 18 years), or provide written assent&#xD;
             (where appropriate) and have a legally authorized representative willing and able to&#xD;
             provide written informed consent, after the nature of the treatment program has been&#xD;
             explained and prior to any treatment-related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Criteria per Intermediate-Size Population Protocol for Glut1 DS&#xD;
&#xD;
          -  Patient qualifies for any other clinical trial designed to progressively evaluate the&#xD;
             safety and efficacy of tripheptanoin in Glut1 DS.&#xD;
&#xD;
          -  Any known hypersensitivity to triheptanoin that, in the judgement of the Treating&#xD;
             Physician, places the patient at an increased risk for adverse events.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ultragenyx Pharmaceutical Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Early Access</last_name>
    <phone>1-415-483-8800</phone>
    <email>EarlyAccess@ultragenyx.com</email>
  </overall_contact>
  <link>
    <url>https://www.ultragenyx.com/our-purpose/supporting-access-for-patients/?#investigational-therapies</url>
    <description>Access to Investigational Therapies / Requesting Access</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 10, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Expanded Access</keyword>
  <keyword>Compassionate Use</keyword>
  <keyword>Carnitine Palmitoyltransferase Deficiency</keyword>
  <keyword>CPT I</keyword>
  <keyword>CPT II</keyword>
  <keyword>Very Long Chain acyl-CoA Dehydrogenase Deficiency</keyword>
  <keyword>VLCAD</keyword>
  <keyword>Long Chain 3-hydroxy-acyl-CoA Dehydrogenase Deficiency</keyword>
  <keyword>LHCAD</keyword>
  <keyword>Trifunctional Protein Deficiency</keyword>
  <keyword>TFP</keyword>
  <keyword>Carnitine-acylcarnitine Translocase Deficiency</keyword>
  <keyword>CACT</keyword>
  <keyword>Long Chain Fatty Acid Oxidation Disorders</keyword>
  <keyword>LC-FAOD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbohydrate Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

